BPC-157 + KPV
One reached human trials. The results were never published.
BPC-157 was discovered in human stomach fluid and went into a Phase 2 trial for ulcerative colitis. Nothing came out. KPV has the most specific delivery argument of any peptide sold today, and it has never been in a human trial at all. People run them together, which nobody has studied.
Both compounds came out of the tissue they are aimed at.
People run this for gut symptoms that have not settled with the usual approaches: flares, cramping, ongoing inflammation, the aftermath of a bad course of antibiotics. The draw is that it splits the job cleanly. One compound is aimed at rebuilding the lining, the other at calming the inflammation sitting on top of it, and few stacks divide the work that neatly.
Most peptide stacks pair compounds that happen to be sold near each other. Both halves of this one were found in the systems they target, which is a better starting point than most combinations get.
BPC-157 was pulled out of human stomach fluid in the early 1990s, where it appeared to be protecting the tissue around it.[4] Its first recorded effects were all in the gut: stomach ulcers healing, the gut lining holding up better, less inflammation in the intestines of rats. The gut is where it came from, before anyone thought to try it on tendons.
KPV is the last three amino acids of alpha-MSH. The full hormone darkens skin and calms inflammation at the same time. Cut the tail off and you keep the anti-inflammatory half without the pigment half.
It got its shot at human evidence, and the data never came out.
A Croatian drug company called Pliva took BPC-157 into human testing for inflammatory bowel disease. In their paperwork it was called PL 14736. A Phase 1 safety study in healthy volunteers found it well tolerated. A Phase 2 trial in ulcerative colitis was run. The results have never been published.[3]
As of 2026 there are still no published Phase 2 or Phase 3 randomised controlled trials of BPC-157 in humans for any indication.[5]
Companies stop publishing for many reasons. Funding runs out, a compound gets deprioritised, a programme is sold. Nobody outside Pliva knows which applies here, and reading failure into the silence has no more support than reading success into it.
This matters for how you read everything else about BPC-157. A compound with hundreds of rodent studies and no published human outcome data is in a different category from one nobody ever tried to test. The attempt was made. The answer exists somewhere and was never shared.
A transporter that shows up when the gut is inflamed.
Nearly every peptide has to be injected, because the digestive system breaks proteins apart before they reach the blood. KPV is one of very few with a documented route around that.
Cells pull small peptides inward through a transporter called PepT1. KPV is three amino acids long, small enough for PepT1 to carry it. In a healthy colon PepT1 is barely present. In chronic inflammatory disease and colitis, expression rises.[2]
So inflamed tissue pulls the compound in harder, at exactly the moment you would want it to. In mouse colitis studies KPV went into the drinking water. Researchers then checked the tissue under a microscope and measured the chemical signals that drive inflammation.[1] Even at very low concentrations it quieted two of those signalling routes.
That is a more specific mechanism story than almost anything else sold in this category. It is also entirely from mice and cell lines. Essentially no completed human trials of KPV exist.[6]
Animal colitis models, three of them.
Animal results have historically translated badly to people for peptide healing compounds,[5] which is the reason the unpublished Phase 2 matters so much. It was the one place the translation question could have been answered.
Precision that the underlying studies do not support.
Pages selling these compounds quote hard numbers. Inflammatory markers down 60%. IL-6 down 45 to 55%. TNF-alpha down 40 to 50%. Improvement in 7 to 14 days. IL-6 and TNF-alpha are signalling molecules the body uses to switch inflammation on.[8]
Each figure comes from one rodent experiment. One way of inducing the disease, one moment chosen to measure it. Quoted as a range with no study named, they read as settled properties of the compound. A drop in a mouse signalling molecule after chemically induced colitis predicts nothing about a person with ulcerative colitis.
The same pages publish doses worked out from those animal studies. No human trial has set a dose for either compound. Scaling a rodent dose by body weight is arithmetic dressed as evidence.
Both compounds moved in 2026.
KPV was removed from Category 2 in April 2026, and in July 2026 the Pharmacy Compounding Advisory Committee recommended it for the 503A Bulks List, the register of substances compounding pharmacies are allowed to make medicines from. That recommendation has not been finalised.[6] BPC-157 went through the same July 2026 advisory round.
Neither is FDA approved for anything. Both are sold as research chemicals. A committee recommendation is advice to the agency, and turning advice into a rule takes eight to twenty-four months when it happens at all.
What people ask about the gut stack
Has BPC-157 been tested in humans?
Partly. A Phase 1 safety study in healthy volunteers found it well tolerated, and a Phase 2 trial in ulcerative colitis was run by Pliva in Croatia under the designation PL 14736. The Phase 2 results have never been published. As of 2026 no Phase 2 or Phase 3 randomised controlled trial of BPC-157 has been published for any indication.
Why do people take KPV orally when most peptides have to be injected?
KPV is only three amino acids long, small enough to be carried into cells by a transporter called PepT1. PepT1 is barely present in a healthy colon and rises in chronic inflammatory disease, so inflamed tissue pulls the compound in more strongly. The evidence for this is from mouse colitis models and cell lines, with essentially no completed human trials.
Has anyone studied BPC-157 and KPV together?
No. We found no study giving both compounds in combination, in animals or in people. Each has its own animal literature and the pairing has none. This is our own searching rather than a systematic review, and we will correct this page for anyone who can point to a trial.
Is BPC-157 legal?
It has no FDA approval for any use and is sold as a research chemical. An FDA advisory committee reviewed it in July 2026. KPV went through the same round, after coming off the restricted list in April. Neither recommendation has been finalised into a rule, and that process typically runs eight to twenty-four months.
Does the rodent evidence mean it will work for my ulcerative colitis?
Nobody can say. The rodent evidence is substantial and holds up across several colitis models. But animal results have translated badly to people for this class of compound, and the one trial built to settle the question produced nothing public. Approved treatments for ulcerative colitis do exist and do have trial evidence. The goal doctors work toward now is healing the gut lining itself, not only easing symptoms, and that is the conversation to have with a gastroenterologist.
What does this stack cost?
About $44 for one vial of each at the cheapest single-compound listings we track, as of 13 September 2026. KPV also sits inside the KLOW blend alongside GHK-Cu and TB-500, so anyone running KLOW is already taking both compounds in this stack. Compare against the other stacks.
Every reference carries how it was read.
- 01Dalmasso et al., PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. PMID 18242607.
- 02PepT1 expression in colon: minimal in health, rising in chronic inflammatory disease and colitis.
- 03BPC-157 as PL 14736, Pliva Croatia: Phase 1 safety in healthy volunteers, Phase 2 in ulcerative colitis, results unpublished. Plus TNBS colitis rat data attributed to Duzel et al., 2017, World Journal of Gastroenterology.
- 04BPC-157 isolated in the early 1990s as a protective factor in human gastric secretions.
- 05No published Phase 2 or Phase 3 randomised controlled trials of BPC-157 in humans for any indication as of April 2026. Note on poor historical animal-to-human translation for peptide healing compounds.
- 06KPV: essentially no completed human clinical trials; removed from Category 2 April 2026; PCAC recommended for 503A Bulks List July 2026, not finalised.
- 07Vuksic et al., BPC 157 heals ileoileal anastomosis in the rat. PMID 17713731.
- 08Commercial pages publishing percentage reductions in inflammatory markers and microgram-per-kilogram dosing for BPC-157 in colitis.
- 09Peptide Decoding vendor pricing data, 12 September 2026. Single-compound listings only.